1 terminated, 1 withdrawn. 1 Early Phase 1, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Withdrawn 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Robert Fox: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Evaluating the Safety of Myeliviz Myelin-Targeting PET Agent [11C]MeDAS - Healthy | Early Phase 1 | Withdrawn | Robert Fox | 2024-07-24 | 2025-02-17 | |
| Safety of Bryostatin in Patients With MS Bryostatin 1 - Multiple Sclerosis | Phase 1 | Terminated | Robert Fox | 4 | 2024-06-26 | 2026-03-31 |
Demyelinating Diseases (1) · Multiple Sclerosis (1)
N-methyl-4,4'-diaminostilbene (1) · bryostatin 1 (1)
United States (2)
Robert J Fox, MD (1)